January 16, 2021, Richard Kim notified Intercept Pharmaceuticals, Inc. (the “Company”) of his decision to resign from
his position as the Company’s President, U.S. Commercial & Strategic Marketing, effective February 15, 2021, in order
to pursue other opportunities. Mr. Kim’s resignation was not the result of any disagreement regarding any matter related
to the Company’s operations, policies or practices.
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
INTERCEPT PHARMACEUTICALS, INC.
/s/ Sandip Kapadia
Name: Sandip Kapadia
Title: Chief Financial Officer and Treasurer
Date: January 20, 2021
makes a similar move, sign up!
Other recent filings from the company include the following:
Intercept Pharmaceuticals's Chief Qual. Officer & SVP Ops. just disposed of 2,455 shares - Jan. 13, 2022
Departure of Directors or Certain - Jan. 10, 2022
Statement of changes in beneficial ownership of securities - Jan. 4, 2022
SVP of Intercept Pharmaceuticals just disposed of 2,455 shares - Jan. 4, 2022
Intercept Pharmaceuticals's Chief Human Resources Officer just disposed of 1,712 shares - Jan. 4, 2022